PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review

Дата публикации: 16-07-2026 00:00:00

This systematic review and meta-analysis compares progression-free survival among patients with hormone receptor–positive/ERBB2-negative metastatic breast cancer, as assessed by blinded independent central review vs local investigators.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Tissue-Free vs Tumor-Informed Circulating Tumor DNA Assays in Early Triple Negative Breast Cancer	0	12.99	13-08-2026
2	Neoadjuvant Immune Checkpoint Inhibitors in Early Breast Cancer	0	7.64	01-10-2024
3	Circulating Tumor DNA in Early Breast Cancer	0	9.02	01-07-2026
4	PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression	0	15.58	01-07-2026
5	Regional differences in chemotherapy treatment for breast cancer may affect survival, Swedish study finds	0	6.96	13-08-2026
6	Magnetic Resonance Imaging in Prostate Cancer Screening	0	9.31	01-06-2024
7	No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection	0	5	22-06-2026
8	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	0	18.85	30-07-2026
9	Individualized Stereotactic Ablative Radiotherapy for Lung Tumors	0	6.6	01-11-2023
10	Treatment Dependent Response Modeling Using Morphologic and Qualitative Features from Perfusion and Contrast-Enhanced Susceptibility Imaging in Undifferentiated Pleomorphic Sarcoma: A Comparison of Radiation Alone Versus Consecutive Chemotherapy and Radiation	0	13.58	07-08-2026

Классификация: Мнения. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.34. Источник: archderm.jamanetwork.com.